Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: GATT legislation

Executive Summary

GATT legislation: Sen. Hatch (R-Utah) pledges to begin hearings in the Judiciary Committee on pharmaceutical patent issues on Feb. 27, 1996 and hold a mark-up by the end of March, according to a Dec. 13 letter to Sen. Pryor (D-Ark.). Pryor's legislation, which would permit generic companies to market products during the extended patent period granted by GATT, was referred to the Judiciary Committee in a 49-48 vote when it was offered as an amendment to the partial-birth abortion ban bill the week of Dec. 8 ("The Pink Sheet" Dec. 11, T&G-7)...

Latest Headlines
See All
UsernamePublicRestriction

Register

PS027386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel